StoxGranules India vs Caplin Point Laboratories: share price & financials comparison
NSE: GRANULES vs CAPLIPOINT · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Granules India vs Caplin Point Laboratories at a glance
Granules India (GRANULES) has a market capitalisation of ₹21,813 Cr, against ₹18,107 Cr for Caplin Point Laboratories (CAPLIPOINT). Over the past year Granules India has returned +40.0%, compared with +17.9% for Caplin Point Laboratories. On valuation, Caplin Point Laboratories trades at a lower P/E of 27.2 versus 30.6. Caplin Point Laboratories earns a higher return on equity (18.6% vs 10.9%). Granules India comes out ahead on growth and momentum. Caplin Point Laboratories comes out ahead on size, valuation, profitability, financial health and technicals. Across the scored metrics below, Granules India leads on 8 and Caplin Point Laboratories on 10. On StoxGud's 10-point checklist, Granules India scores 8/10 and Caplin Point Laboratories scores 9/10.
| Metric | Granules India | Caplin Point Laboratories |
|---|---|---|
| Size | ||
| Market cap | ₹21,813 Cr | ₹18,107 Cr |
| Revenue (latest FY) | ₹5,366 Cr | ₹2,187 Cr |
| Net profit (latest FY) | ₹595 Cr | ₹641 Cr |
| Valuation | ||
| P/E | 30.6 | 27.2 |
| P/B | 3.32 | 5.05 |
| Dividend yield | 0.17% | 0.25% |
| Profitability | ||
| Return on equity | 10.9% | 18.6% |
| Net profit margin | 12.1% | 29.1% |
| Operating margin | 22.7% | 34.8% |
| Growth | ||
| Revenue growth (YoY) | +20.3% | +19.6% |
| Net profit growth (YoY) | +39.2% | +15.8% |
| Revenue CAGR (multi-year) | +10.6% | +15.6% |
| Financial health | ||
| Debt to equity | 0.09 | 0.00 |
| Momentum | ||
| 1-month return | -5.4% | -10.1% |
| 1-year return | +40.0% | +17.9% |
| 3-year CAGR | +31.6% | +29.7% |
| 5-year CAGR | +20.2% | +22.9% |
| 10-year CAGR | +21.4% | +20.1% |
| Distance from 52W high | -12.1% | -16.9% |
| Technicals | ||
| RSI (14) | 42 | 59 |
| Price vs 200-day avg | +7.5% | +9.5% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Granules India | Caplin Point Laboratories |
|---|---|---|
| Price above 50-day average | ✗ | ✗ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✓ |
| Score | 8/10 | 9/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Granules India or Caplin Point Laboratories?
Granules India has a market cap of ₹21,813 Cr and Caplin Point Laboratories has a market cap of ₹18,107 Cr as of 06 Nov 2026.
Which has a lower P/E, Granules India or Caplin Point Laboratories?
Caplin Point Laboratories has the lower P/E: Granules India trades at 30.6 and Caplin Point Laboratories at 27.2.
Which gave better returns in the last year, Granules India or Caplin Point Laboratories?
Granules India did better: Granules India returned +40.0% and Caplin Point Laboratories returned +17.9% over one year.
Is Granules India or Caplin Point Laboratories a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Granules India scores 8/10 and Caplin Point Laboratories scores 9/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.